Non-Anticoagulant Activities of Low Molecular Weight Heparins-A Review
Low molecular weight heparins (LMWHs) are derived from heparin through chemical or enzymatic cleavage with an average molecular weight (Mw) of 2000-8000 Da. They exhibit more selective activities and advantages over heparin, causing fewer side effects, such as bleeding and heparin-induced thrombocyt...
Saved in:
Main Authors: | Ke Feng (Author), Kaixuan Wang (Author), Yu Zhou (Author), Haoyu Xue (Author), Fang Wang (Author), Hongzhen Jin (Author), Wei Zhao (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
by: Janis Kay Shute
Published: (2023) -
Effects of low-molecular-weight heparin and unfractionated heparin on patients with exertional heat stroke with thrombocytopenia: A prospective study
by: Li Cheng, et al.
Published: (2019) -
COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
by: Alessandra F. Perna, et al.
Published: (2020) -
Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis
by: Wei Kang, et al.
Published: (2024) -
Low molecular weight heparin in COVID-19: benefits and concerns
by: Adham Makarem, et al.
Published: (2023)